Probiodrug AG
Probiodrug to Present and Attend European Conferences in April 2016
HALLE/SAALE, Germany, 31 March 2016 - Probiodrug AG ("Probiodrug", Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease, announces that the company is scheduled to attend the following conferences:
1. BIO Europe Spring
4-6 April 2016, Kistamässan Convention Center, Stockholm, Sweden
Dr Konrad Glund, CEO, to present on Tuesday, 5 April 2016 at 04:15pm CET in E5, level 0
BIO-Europe Spring is the premier springtime partnering conference which annually attracts an international "who's who" from biotech, pharma and finance for three days of high caliber networking.
2. 9th Kempen Life Sciences Conference
6-7 April 2016, Kempen & Co offices Amsterdam, The Netherlands
Dr Konrad Glund, CEO, to attend and host meetings at the conference
The Kempen Life Sciences Conference covers the advance of Life Sciences and its increasing impact on business that is set to continue in the 21st century.
3. Swiss Biotech Day
12 April 2016, Congress Center Basel, Switzerland
Dr Konrad Glund, CEO, to present on Tuesday, 12 April 2016 at 04:00pm CET and host meetings
The Swiss Biotech Day is the leading biotechnology conference in Switzerland. This event will bring together more than 500 senior executives from the life science industry across Europe. Programme highlights in 2016 will include key notes from renowned industry experts, the presentation of the Swiss biotech report, and the annual general assembly of the Swiss Biotech Association and a new partnering platform.
4. Deutsche Biotechnologietage
26-27 April 2016, Kongresshalle am Zoo Leipzig, Germany
Dr Konrad Glund, CEO, to present on Tuesday 26th April 2016 04:15pm CET in session Trade Sales and IPOs
The Deutsche Biotechnologietage is a meeting place for more than 800 representatives from the world of business, science and government, including partners from funding institutions and public administration. Through a series of talks, panel discussions and breakfast sessions, the conference discusses the conditions for innovation in biotechnology and the wide range of biotech applications.
###
For more information, please contact:
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume Brophy
Supriya Mathur, Eva Haas, Alexia Faure
Tel: +44 (0) 20 7862 6475
Email: probiodrug@humebrophy.com
The Trout Group
Tricia Truehart
Tel: +1 (646) 378-2953
Email: ttruehart@troutgroup.com
Notes to Editors:
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer's disease.
Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes - the DP4 inhibitors - which provided the basis for a novel class of antidiabetics - the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.
Today Probiodrug's aim is to become a leading company in the development of Alzheimer's disease treatments and to thereby provide a better life for Alzheimer's disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer's disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company's view, with a leading position in this field of research.
About Alzheimer's disease
Alzheimer's disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer's disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, over 46 million people worldwide currently live with the condition and this number is expected to increase to 132 million by 2050. Alzheimer's also has an estimated, global societal cost of US$ 818 billion (World Alzheimer Report 2015).
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.